a n a ly s i s DNA methylation plays a key role in regulating eukaryotic gene expression. Although mitotically heritable and stable over time, patterns of DNA methylation frequently change in response to cell differentiation, disease and environmental influences. Several methods have been developed to map DNA methylation on a genomic scale. Here, we benchmark four of these approaches by analyzing two human embryonic stem cell lines derived from genetically unrelated embryos and a matched pair of colon tumor and adjacent normal colon tissue obtained from the same donor. Our analysis reveals that methylated DNA immunoprecipitation sequencing (MeDIP-seq), methylated DNA capture by affinity purification (MethylCap-seq), reduced representation bisulfite sequencing (RRBS) and the Infinium HumanMethylation27 assay all produce accurate DNA methylation data. However, these methods differ in their ability to detect differentially methylated regions between pairs of samples. We highlight strengths and weaknesses of the four methods and give practical recommendations for the design of epigenomic case-control studies.
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DNA methylation is a common mechanism of epigenetic regulation in eukaryotes. It occurs most frequently at cytosines that are followed by guanines (CpG). High levels of DNA methylation in promoter regions are typically associated with robust gene silencing 1 . Twentyfive years of research on cancer epigenetics have firmly established the prevalence of aberrant DNA methylation in cancer cells [2] [3] [4] [5] [6] . Moreover, recent studies have investigated the role of DNA methylation for neural and autoimmune diseases, its correlation with physiological conditions and its response to environmental influences [7] [8] [9] . Comprehensive mapping of DNA methylation in relevant clinical cohorts is likely to identify new disease genes and potential drug targets, help to establish the relevance of epigenetic alterations in disease and provide a rich source of potential biomarkers 10 . DNA methylation mapping could also facilitate quality control of cultured cells by exploiting the fact that cell states and differentiation potential of stem cells are reflected in their DNA methylation patterns 11 .
Several methods have been developed to map DNA methylation on a genomic scale. Most of these methods combine DNA analysis by microarrays or high-throughput sequencing with one of four ways of translating DNA methylation patterns into DNA sequence information or library enrichment. (i) MeDIP-seq uses an antibody that is specific for 5-methylcytosine to retrieve methylated fragments from sonicated DNA 12, 13 . (ii) MethylCap-seq employs a methyl-binding domain protein to obtain DNA fractions with similar methylation levels [14] [15] [16] . (iii) Bisulfite-based methods use a chemical reaction that selectively converts unmethylated, but not methylated, cytosines into uracils, thus introducing methylation-specific, single nucleotide polymorphisms into the DNA sequence 11, 17, 18 . (iv) Methylation sensitive digestion uses prokaryotic restriction enzymes to selectively fractionate only methylated or only unmethylated DNA [19] [20] [21] .
The diversity of methods to map DNA methylation and the absence of an uncontested commercial market leader raise questions about each method's strengths and weaknesses-questions that researchers have to answer for themselves when selecting the most appropriate technology for any given project. The goal of this study was to comprehensively evaluate four popular methods-MeDIP-seq 12 , MethylCap-seq 14 , RRBS 22 and the Infinium HumanMethylation27 assay 17 with a special emphasis on their practical utility for biomedical research and biomarker development. All four methods are relatively easy to set up because detailed protocols have been published and/or commercial kits are available. We chose RRBS because it targets bisulfite sequencing to a well-defined set of genomic regions with moderate to high CpG density 22 , which makes RRBS substantially more cost efficient than genome-wide bisulfite sequencing. The Infinium HumanMethylation27 assay, also a bisulfite-based method, was included because of its wide use and easy integration with existing genotyping pipelines; it is the only microarray-based method in our comparison. Methods that use tiling microarrays were excluded because they have been benchmarked previously 20 and because next-generation sequencing enables higher resolution and/or higher genomic coverage at competitive cost. Methylation-specific digestion was excluded because no algorithm exists that could accurately infer quantitative DNA methylation data from digested read frequencies 19 . An outline of the experimental and analytical procedure of this technology comparison is shown in Figure 1 . a n a ly s i s RESULTS DNA methylation mapping by four methods Genome-wide DNA methylation mapping is most commonly used as a discovery tool to identify differentially methylated regions (DMRs) as candidates for further research. Typical examples are cancerspecific DMRs, which are increasingly used as biomarkers for cancer diagnosis and therapy optimization 10 . To emulate the case-control approach that is widely used for epigenetic biomarker development, we focused on sample pairs that we statistically compare with each other. Specifically, we selected two human embryonic stem (ES) cell lines that were derived from genetically unrelated embryos 23 , and a matched pair of colon tumor and adjacent normal colon tissue obtained from the same donor. We applied each of the four methods (MeDIPseq, MethylCap-seq, RRBS, Infinium) to all four samples (HUES6 ES cells, HUES8 ES cells, colon tumor and matched normal colon tissue), generating a total of 16 genome-scale DNA methylation maps. All data were processed with a standardized bioinformatic pipeline, and the technical data quality turned out to be similarly high across all samples and methods ( Table 1) .
When plotting the DNA methylation data as genome browser tracks, we found excellent visual agreement between all four methods ( Fig. 2; tracks are available online for interactive browsing: http://meth-benchmark.computational-epigenetics.org/). MeDIPseq and MethylCap-seq gave rise to peaks of methylated DNA that were similar in shape, size and location, indicating that MeDIP-seq's monoclonal antibody and MethylCap-seq's methyl-binding domain enrich for similar DNA fragments. However, MeDIP-seq exhibited higher baseline levels and lower peak heights than MethylCap-seq. This smaller dynamic range is already apparent from Figure 2 (note the different scale of the y axis) and becomes more obvious when plotting MeDIP and MethylCap-seq tracks along an entire chromosome ( Supplementary Fig. 1 ). This observation was quantitatively confirmed by plotting the mean read frequency for enriched and depleted fractions of the genome (Supplementary Fig. 2 ). We also observed high visual agreement between RRBS and Infinium, with the limitation that Infinium covers two orders of magnitude fewer CpGs than RRBS (Table 1) . Finally, the bisulfite-based methods (RRBS, Infinium) generally confirm the results of the enrichment-based methods (MeDIP, MethylCap-seq), although there are deviations in repeat-rich as well as in CpG-poor genomic regions ( Supplementary Fig. 3 ).
Accuracy of DNA methylation mapping
For a more quantitative assessment of measurement accuracy, we compared the results of the three sequencing-based methods (MeDIP-seq, MethylCap-seq, RRBS) with the Infinium HumanMethylation27 assay as a common reference (Fig. 3) . The Infinium assay was used as reference because its quantitative accuracy has been established in previous studies 17, 24 , which reported correlation coefficients around 0.9 relative to the GoldenGate and MethyLight assays. Note, however, that the probes of the Infinium assay cover only a small percentage of all CpGs in the genome and are preferentially located in unmethylated promoter regions. To compensate for this potential source of bias, we calculated two correlation coefficients, one across the entire spectrum of methylation levels and the other focusing only on those CpGs that exhibit at least 20% methylation according to the Infinium assay.
RRBS and Infinium data can be compared directly and without normalization, because both methods measure absolute DNA methylation levels. For a total of 5,088 single CpGs that were covered by both an Infinium probe and at least five RRBS reads, we observed a Pearson correlation of 0.92 across all DNA methylation levels and a Pearson correlation of 0.83 when we excluded unmethylated CpGs. Because neighboring CpGs tend to exhibit highly correlated DNA methylation levels 18, 25 , we also evaluated the correlation for RRBS measurement averages over a 200-base pair (bp) sequence window around each Infinium probe. Again, we observed excellent agreement between the two methods ( Fig. 3c) , with an overall Pearson correlation of 0.92 across all DNA methylation levels and a Pearson correlation of 0.84 when we excluded unmethylated CpGs. This second comparison supports the hypothesis that a single-CpG measurement can often act as an indicator of the DNA methylation levels at neighboring, unmeasured CpGs.
Comparison with MeDIP-seq and MethylCap-seq is less straightforward because both methods measure the relative enrichment of methylated DNA rather than absolute DNA methylation levels. When we correlated the number of sequencing reads per 1-kb region with the DNA methylation measurements of the Infinium assay, the Pearson correlation did not exceed 0.6 across all DNA methylation levels and 0.4 when we excluded unmethylated CpGs ( Supplementary Fig. 3a,b ). High density of repetitive DNA was identified as a major source of spurious read enrichment in regions with low absolute DNA methylation levels. In contrast, low CpG density gave rise to low read numbers in regions with high levels of DNA methylation ( Supplementary Fig. 3c,d) . The confounding effect of DNA sequence is also visible in Figure 2 . Low read counts can indicate either the relative absence of CpGs (e.g., region 1 in Fig. 2 ) or the absence of DNA methylation in the presence of CpGs (Fig. 2, region 2) ; and strong peaks can occur in genomic regions that are incompletely methylated if the CpG density is sufficiently high to give rise to substantial read enrichment ( Fig. 2, region 3 ). Figure 1 Outline of the DNA methylation technology comparison. Four methods for DNA methylation mapping were compared on two pairs of samples. The resulting 16 DNA methylation maps were bioinformatically analyzed and benchmarked against each other. In addition, clonal bisulfite sequencing was performed on selected genomic regions to validate DNA methylation differences that were detected exclusively by one method. a n a ly s i s It has previously been reported that statistical correction for CpG density can improve the quantification of DNA methylation levels based on MeDIP-seq data 12, 26 . We therefore constructed a linear regression model that corrects for the confounding effect of DNA sequence, and we observe substantially improved results ( Fig. 3a,b) . Across all DNA methylation levels the correlation between the statistically corrected read counts and the DNA methylation measurements of the Infinium assay amounted to 0.84 for MeDIP-seq and to 0.88 for MethylCap-seq. However, the correlations dropped to 0.57 (MeDIP-seq) and 0.66 (MethylCap-seq) when we excluded unmethylated CpGs. These results indicate that MeDIP-seq and MethylCap-seq can distinguish between methylated and unmethylated regions almost as precisely as RRBS, but are less accurate for quantifying the DNA methylation levels in partially methylated genomic regions.
Genomic coverage of DNA methylation mapping
The single-bp resolution of the two bisulfite-based methods comes at the cost of reduced genomic coverage compared to the two enrichmentbased methods. RRBS reads cover less than 10% of the 28 million CpGs in the human genome and Infinium is by design restricted to 27,578 promoter-associated CpGs ( Table 1 ). In contrast, MeDIP-seq and MethylCap-seq are theoretically able to identify methylated genomic regions located anywhere in the genome, although they too are subject to intrinsic limitations 27 . To assess the empirical genomic coverage of each method, we calculated the number of reads (MeDIP-seq, MethylCap-seq) or CpG methylation measurements (RRBS, Infinium) for each of the following genomic regions: (i) CpG islands, (ii) gene promoters and (iii) a 1-kb tiling of the genome. The results are shown in Figure 4 , and coverage details for a total of 13 types of genomic regions are available online (http://meth-benchmark.computational-epigenetics.org/).
As expected, MeDIP-seq and MethylCap-seq provide broad coverage of the genome, whereas RRBS and Infinium are more restricted to CpG islands and promoter regions. However, the practically relevant differences in genomic coverage are lower than Figure 4 may suggest. This is because a minimum number of reads are required in at least one sample to reliably detect differential methylation among a given pair of samples. We illustrate this point by two statistical power calculations, which were performed with G*Power 3 (ref. 28) . Assume that a genomic region is covered by five MeDIP-seq or MethylCapseq reads in one sample. Then it has to contain at least 20 reads in the second sample to be detected as hypermethylated (assuming a statistical power of 80% and a P-value of 5% without multipletesting correction). Similarly, RRBS would detect a DNA methylation increase from 30% to 70% only when at least 25 measurements are available in each sample (again assuming a statistical power of 80% and a P-value of 5% without multiple-testing correction).
Identification of differentially methylated regions
Genome-wide DNA methylation mapping is most commonly used for detecting DNA methylation differences, for example, between diseased and healthy tissue or between genetically modified and unmodified control cells. To assess how well MeDIP-seq, MethylCapseq and RRBS perform on this task, we developed a bioinformatic method that identifies statistically significant DMRs from multiple types of sequencing data (the Infinium assay requires a different approach and is discussed in a separate section below). For a predefined set of genomic regions we count the numbers of sequenced reads (for MeDIP-seq and MethylCap-seq) or, alternatively, the numbers of methylated versus unmethylated CpGs (for RRBS), and we test for statistically significant differences between two samples using Fisher's exact test. When applied to a complete tiling of the human genome, this method performs genome-wide DMR detection. Alternatively, it can be targeted to specific region types such as CpG islands, gene promoters or putative enhancers, which often leads to more sensitive detection of small differences because the multiple-testing burden is reduced compared to genome-wide DMR detection. We pursued both the unbiased and the annotation-guided approach in parallel, focusing our comparison on three types of genomic regions: (i) CpG islands, (ii) gene promoters and (iii) a 1-kb tiling of the genome ( Fig. 5 and Supplementary Figs. 4-8) .
Overall, we observed high correlation for each of the two sample pairs, but also outliers suggesting the presence of DMRs. Based on the The unique read rate was calculated by dividing the number of reads that map to a unique position in the genome (defined by chromosome, read start position and strand) by the total number of aligned reads. c Samples 11 and 12 were part of a sequencing-optimization run that resulted in lower sequencing yield and reduced alignment rates. Four lanes were sequenced to reach the target of 30-40 million reads per sample and method. a n a ly s i s RRBS data, we obtained Pearson correlations around 0.9 for all three region types, both between the two ES cell lines (HUES6 and HUES8) and between the colon tumor and matched normal colon tissue. For MethylCap-seq and MeDIP-seq, the correlations were somewhat lower and ranged from 0.75 to 0.92 ( Fig. 5 and Supplementary Figs. 4-8 ). Using the DMR detection algorithm (Online Methods), we identified several hundred to several thousand DMRs in both sample pairs. There was substantial, but by no means perfect, overlap between the DMRs identified by all three methods. For the two human ES cell lines, 277 out of 44,440 CpG islands were detected as differentially methylated by each of the three methods ( Fig. 5d ). Pairwise comparisons for each sample and region type ( Supplementary Figs. 4-8 ) confirmed that the agreement between the three methods was statistically significant in all cases (P < 0.01, Fisher's exact test). In total, we observed that up to 1,000 CpG islands, 405 promoter regions or 1,924 of the 1-kilobase tiling regions (that is, <0.1% of the genome) were detected as differentially methylated by at least two methods. Note, however, that it is not possible to combine these values into a single sum of DMRs because many CpG islands overlap with promoter regions and every CpG island and promoter region overlaps with at least one tiling region. Nor does the number of differentially methylated tiling regions provide an accurate estimate of the 'true' number of DMRs because a sizable number of DMRs are no longer statistically significant when split into 1-kb regions. Despite these conceptual difficulties, which preclude us from giving a single 'true' number of DMRs for each sample pair, our data clearly indicate that-on average-MethylCap-seq identifies more DMRs than RRBS, and MeDIP-seq identifies the fewest DMRs. This order was observed not only when we focused on the total number of DMRs per method, but also when we considered only those DMRs that were detected by at least two methods, indicating that the comparison is not distorted by high numbers of method-specific artifacts.
Validation of method-specific DMRs
To pinpoint potential problems of MeDIP-seq, MethylCap-seq or RRBS, we manually inspected a large number of regions that were identified as significant DMRs by only one method. The most common reasons why DMRs identified by one method were missed by the other methods were insufficient genomic coverage (RRBS, Infinium) and low read numbers conferring insufficient statistical power to detect differential DNA methylation (MeDIP-seq, MethylCap-seq).
No cases were identified in which the RRBS and Infinium data were in direct contradiction with each other. However, we could identify a few cases in which MeDIP-seq or MethylCap-seq were inconsistent with RRBS and/or Infinium data. These were almost exclusively located in repetitive regions, indicating that high copynumber repeats can amplify minor differences in the efficiency of methylated DNA enrichment and give rise to a small number of spurious DMRs. In contrast, RRBS seems more robust toward such fluctuations because it measures DNA methylation based on the DNA sequence of the reads in a given region, rather than on their read frequency. We also assessed whether copy-number variation was a major confounding factor for DMR discovery. This does not seem to be the case for our data. The vast majority of DMRs were shorter than 10 kb ( Supplementary Fig. 9 ), whereas it is not uncommon for cancer-specific as well as germline-transmitted copy-number variations to extend for much longer distances 29, 30 . a n a ly s i s
As an additional validation, we selected eight method-specific DMRs based on the ES cell comparison, and we investigated DNA methylation patterns in the two ES cell lines by clonal bisulfite sequencing ( Table 2) . These genomic regions were handpicked such that one method clearly identified them as DMRs whereas the two other methods did not show a trend in either direction. Note that this preselection makes the validation substantially harder than confirming randomly selected DMRs, because the magnitude of the DNA methylation difference tends to be lower for method-specific DMRs than for DMRs that are detected by multiple methods. As an additional complication, some of the selected DMRs are highly repetitive or overlap with known copy-number variations. Sequencing an average of 11 clones per sample and region we were able to confirm three out of three MethylCap-seq-specific DMRs and two out of two RRBS-specific DMRs. In contrast, two MeDIP-seq-specific DMRs could not be confirmed, and for the third region the agreement was marginal ( Table 2 and Supplementary Data 1) .
To assess the practical relevance of the method-specific differences, we asked whether biologically interesting hits were missed by any of the three methods. For this analysis we focused on the colon samples because of the large number of genes with a known or suspected role in colon cancer. Our results show that several interesting DMRs are detected by all methods, including tumor-specific hypermethylation in the promoters of GATA2 (ref. The effect of sequencing depth on mapping performance MeDIP-seq, MethylCap-seq and RRBS use DNA sequencing as a way of counting DNA fragments to determine the percentage of methylation-enriched reads that align to specific genomic regions (MeDIP-seq, MethylCap-seq) or to calculate the ratio of methylated and unmethylated cytosines at single CpGs (RRBS). Conceptually, sequencing can be thought of as random sampling from a large pool of DNA fragments. It is therefore expected that the performance of these methods increases when sequencing more DNA fragments, until it levels off as the sequencing depth approaches saturation. To quantify (a-c) Absolute DNA methylation levels were calculated from the data obtained by MeDIPseq (a), MethylCap-seq (b) and RRBS (c), respectively, and compared to DNA methylation levels determined by the Infinium assay. For MeDIP-seq and MethylCap-seq, sequencing reads were counted in 1-kb regions surrounding each CpG that is interrogated by the Infinium assay, and a regression model was used to infer absolute DNA methylation levels. Scatter plots and correlation coefficients were calculated on a test set that was not used for model fitting or feature selection. For RRBS, the DNA methylation level was determined as the percentage of methylated CpGs within 200 bp surrounding each CpG that is interrogated by the Infinium assay. Data shown are for the HUES6 human ES cell line, and regions that did not have sufficient sequencing coverage were excluded.
Figure 4
Genomic coverage of MeDIP-seq, MethylCap-seq, RRBS and Infinium. Genomic coverage was quantified by the number of DNA methylation measurements that overlap with CpG islands (top row), gene promoters (center row) and a 1-kb tiling of the genome (bottom row). For MeDIP-seq and MethylCap-seq, the number of measurements is equal to the number of unique sequencing reads that fall inside each region. For RRBS, it refers to the number of valid DNA methylation measurements at CpGs within each region (one RRBS sequencing read typically yields one measurement, but can also give rise to more than one measurement if it contains several CpGs). For Infinium, the number of measurements is equal to the number of CpGs within each region that are present on the HumanMethylation27 microarray. CpG islands were calculated using CgiHunter (http://cgihunter.bioinf.mpi-inf.mpg.de/), requiring a minimum CpG observed versus expected ratio of 0.6, a minimum GC content of 0.5 and a minimum length of 700 bp 55 . Promoter regions were calculated based on Ensembl gene annotations, such that the region starts 1 kb upstream of the annotated transcription start site (TSS) and extends to 1 kb downstream of the TSS. The genomic tiling was obtained by sliding a 1-kb window through the genome such that each tile starts at the position where the previous tile ends. No repeat-masking was performed for any of the three types of genomic regions. Data are shown for the HUES6 human ES cell line. a n a ly s i s this effect, we repeated the accuracy analysis ( Fig. 3 ) and the DMR detection ( Fig. 5 ) on randomly sampled subsets of sequencing reads. First, we benchmarked each method against the Infinium data, assessing their ability to quantify DNA methylation levels based on reduced read numbers (Supplementary Fig. 10) . The results show that all three methods give rise to accurate DNA methylation measurements based on as little as 20% of the total read coverage, and almost no improvement was observed between 50% and 100% sequencing depth. Although these data suggest that relatively low sequencing depths are often sufficient for obtaining accurate DNA methylation levels, this cannot be generalized to the entire genome. Infinium probes tend to be located in CpG-rich genomic regions, which are also preferentially covered by MeDIP-seq, MethylCap-seq and RRBS measurements ( Fig. 4) , such that saturation is reached earlier in the vicinity of Infinium probes than in CpG-poor genomic regions. Second, we tested how many DMRs were still detected among the two sample pairs when the number of sequencing reads in each of the samples was reduced (Supplementary Fig. 11 ). For MeDIP-seq, the number of detected DMRs dropped to less than half when the sequencing depth was reduced to 50%, and there was little indication that the number of MeDIP-seq DMRs approaches saturation even at the highest sequencing depth. For MethylCap-seq the decrease in the number of detected DMRs is less dramatic and there is a trend toward saturation. RRBS quickly approaches saturation especially for the ES-cell comparison (Supplementary Fig. 11) . Overall, the saturation analysis reinforced a conceptual difference between RRBS on the one hand and MeDIP-seq and MethylCap-seq on the other hand. In RRBS, all sequencing is focused on a well-defined, CpGrich 'reduced representation' of the genome, which leads to relatively early saturation but limited coverage of DMRs in CpG-poor genomic regions. In contrast, MeDIP-seq and MethylCap-seq reads are widely distributed over the genome (albeit with a significant tendency toward high coverage in CpG-rich regions), and deep sequencing increasingly uncovers weak DMRs located in CpG-poor genomic regions.
DNA methylation mapping of repetitive DNA DNA methylation differences in repetitive regions have frequently been ignored by genome-wide studies, due to technical difficulties such as ambiguous read alignment (for sequencing) and crosshybridization (for microarrays). This is unfortunate given that loss of DNA methylation in repetitive DNA was the first epigenetic alteration shown to play a role in cancer 4 and has been an area of active research ever since 38 . In the current study, we explored two complementary approaches to test for repeat-associated DNA methylation differences. First, we included repetitive regions alongside nonrepetitive regions in the DMR detection described above ( Fig. 5 and Supplementary  Figs. 4-8) , rather than discarding all sequencing reads that map to repetitive portions of the genome. It was thus possible to identify repeat-associated DMRs in a similar way as nonrepetitive DMRs, and we could validate several such cases by clonal bisulfite sequencing ( Table 2) . However, the focus on specific genomic regions makes it difficult to detect global trends that affect certain repeat classes independent of their exact location in the genome. We therefore developed a second approach, which was motivated by the common origin of many repetitive regions from a small number of retrotransposons. The basic concept was to align sequencing reads to prototypic sequences (e.g., of Alu and L1 elements) to obtain DNA methylation measures per repeat class rather than per repeat instance.
To that end, we obtained a manually curated list of 1,267 prototypic repeat sequences that spans the spectrum of repetitive DNA present in the human genome 39 , and we aligned the sequencing reads of all three methods to this collection of repeat sequences. Approximately 20% of all MeDIP-seq, MethylCap-seq and RRBS reads could be aligned with high confidence, enabling us to estimate the global DNA methylation levels for 553 prototypic repeat sequences. The results of the three methods were in excellent agreement with each other (Supplementary Data 2) and detected substantial differences in the DNA methylation levels of different repeat classes. Among Alu, SVA (SINE-VNTR-Alus) and satellite repeat sequences we observed consistently high levels of DNA methylation, whereas most LINE (long interspersed nuclear elements), LTR (long terminal repeat) and DNA repeat sequences exhibited low levels of DNA methylation in the four samples that we investigated. However, we found that the repeat sequences with the highest copy-number throughout the genome were highly methylated for all repeat classes.
When we compared the DNA methylation levels in the two sample pairs (Supplementary Data 3) , we observed widespread but relatively moderate hypomethylation in the colon tumor relative to matched normal colon tissue. The most common targets were Alu, SVA and satellite repeat sequences, consistent with previous reports about cancer-specific hypomethylation 38 . A notable difference was identified between the two ES cell lines on the one hand and the two colon samples on the other hand: the only human-specific LINE repeat sequence in our collection (L1HS_5end) exhibited high levels of DNA methylation in the two colon samples, but was largely unmethylated and even marked by histone H3K4 trimethylation in the two ES cell Regions with insufficient sequencing coverage were excluded. (d) The Venn diagram displays the total number and mutual overlap of differentially methylated CpG islands that could be identified by each method. CpG islands were classified as hypermethylated or hypomethylated (depending on the directionality of the difference) if the absolute DNA methylation difference exceeded 20 percentage points (for RRBS) or if there was at least a twofold difference in read number between the two samples (for MeDIP-seq and MethylCap-seq)-but only if Fisher's exact test with multiple-testing correction gave rise to an estimated false-discovery rate of differential DNA methylation that was <0.1. a n a ly s i s lines (Supplementary Data 2) . These data suggest that young retrotransposons find ways to evade silencing by DNA methylation in pluripotent cells, which may contribute to their ability to maintain activity in spite of an elaborate epigenetic genome defense 40 .
DMR discovery using the Infinium assay
Our study used the Infinium HumanMethylation27 assay as a common reference for evaluating the accuracy of the sequencing-based methods, which was justified by prior studies showing high quantitative accuracy of the Infinium assay 17, 24 . However, no prior study investigated the Infinium HumanMethylation27 assay's power to detect DMRs on a genome-wide scale, hence we could not use the Infinium assay as reference when evaluating DMR discovery by the sequencing-based methods. In fact, its low genomic coverage is expected to limit the utility of the Infinium assay for DMR discovery in spite of its well-established accuracy (Fig. 4) . To empirically address this question, we initially performed statistical testing in much the same way as was done for Figure 5 . However, most CpG islands were covered by only two Infinium probes, which resulted in low statistical power to detect significant differences. Specifically, paired-samples t-tests identified just three significant DMRs among the ES cell lines and two DMRs between the colon tumor and matched normal colon tissue (data not shown). Thus, we reformulated our question and asked how many true DMRs exhibited suggestive (albeit insignificant) DNA methylation differences in the Infinium data. As an approximation of true DMRs, we focused on those CpG islands that were detected by at least two sequencing-based methods (which are unlikely to contain a high number of technical artifacts according to the comparative validations described above). Between the two ES cell lines a total of 1,000 consensus DMRs were identified (corresponding to the sum of all center fields in Fig. 5) , of which 251 were covered by at least one Infinium probe. Similarly, we identified 463 consensus DMRs between the colon tumor and matched normal colon tissue, of which 177 were covered by at least one Infinium probe. In most cases, the directionality of the difference was consistent between the consensus DMRs and the Infinium data (Supplementary Fig. 12 ). But when we imposed a minimum threshold of 20 percentage points DNA methylation difference in the same way as for RRBS, the number of Infiniumdetected DMRs dropped to 162 (ES-cell comparison) and 95 (colon cancer comparison). In other words, the Infinium assay detected approximately one-fifth of the consensus DMRs that we identified by the sequencing-based methods.
DISCUSSION
Over the last decade, DNA methylation mapping has played an important role in establishing the prevalence of altered DNA methylation in cancer cells 41, 42 . More recently, researchers have also started to systematically study the role of DNA methylation in a wide range of non-neoplastic diseases 43 . This is indeed a good time to probe for epigenetic alterations that contribute to human diseases. Genome-wide association studies have been completed for all common diseases and point to a major role of nongenetic factors in the etiology of most diseases 44 . Furthermore, it has been suggested that epigenetic events could provide a tractable link between the genome and the environment, with the epigenome emerging as a biochemical record of relevant life events 45, 46 . Systematic investigation of these topics requires powerful, accurate and cost-efficient methods for identifying DNA methylation differences across many samples.
The goal of this study was to evaluate current methods for global DNA methylation mapping and to compare their performance when applied under real-world conditions. To mimic a typical diseasecentered case-control study, we worked with primary patient material (colon samples) and used lower amounts of input DNA than in most previous studies (MeDIP-seq: 300 ng; MethylCap-seq: 1 μg; RRBS: Experimental validation of method-specific DMRs between two ES cell lines (HUES6 and HUES8). The table summarizes the results of clonal bisulfite sequencing for eight regions that showed clear-cut DNA methylation differences according to one method but not according to the other two. The P values in column 3 were calculated from the clonal bisulfite sequencing data using Fisher's exact test, based on the DNA methylation levels of individual CpGs. The Q values in columns 4-6 were derived from the DNA methylation maps as described in the Online Methods. One out of three MeDIP-seq-specific DMRs, three out of three MethylCap-seq-specific DMRs and two out of two RRBS-specific DMRs could be confirmed by clonal bisulfite sequencing data (bold print). All genomic coordinates are relative to the NCBI36 (hg18) genome assembly and refer to the amplicon on which the validation was performed. A detailed documentation of the validation experiments is available in Supplementary Data 1. a n a ly s i s 50 ng; Infinium: 1 μg). We focused on cell types that are known to exhibit relatively moderate DNA methylation differences 31, 47 , in contrast to the massive DNA methylation alterations that are frequently observed in cultured somatic cells 11 and cancer cell lines 48 .
Finally, because all four methods included in the current study are widely available and not excessively costly, there are few obstacles to using this technology comparison as a blueprint for individual laboratory efforts as well as large-scale epigenomic case-control studies investigating the epigenetics of human diseases.
Overall, our data confirmed that all four methods provide accurate DNA methylation measurements and can be used to detect DMRs in clinical samples. In terms of accuracy, the bisulfite-based methods (RRBS, Infinium) performed slightly better than the enrichmentbased methods and did not require any statistical correction of CpG bias. Furthermore, the genomic coverage was moderately higher for MethylCap-seq than for MeDIP-seq, RRBS coverage was by design focused on CpG-rich regions and the Infinium assay covered a relatively small number of preselected genomic regions.
Despite the striking differences in genomic coverage, a substantial fraction of DMRs detected by MeDIP-seq or MethylCap-seq were also identified by RRBS, and vice versa. This somewhat counterintuitive observation can be explained by the role of region-specific read coverage for the ability to identify statistically significant DMRs. If a genomic region is CpG poor and thus rarely sequenced by MeDIPseq or MethylCap-seq, both methods have low statistical power to detect differential DNA methylation. In contrast, CpG-rich genomic regions tend to be more amenable to DMR detection by MeDIP-seq and MethylCap-seq and are also frequently covered by RRBS measurements. Finally, we observed that MethylCap-seq was able to detect roughly twice as many DMRs as MeDIP-seq at comparable sequencing depths, RRBS detected more DMRs than MeDIP-seq but fewer DMRs than MethylCap-seq, and the Infinium assay detected only 20% of the consensus DMRs identified by the sequencing-based methods. These differences could be reproduced in two independent pairwise comparisons, providing strong indication that they are robust across biological replicates and cannot be explained by random experimental variation. On the other hand, we used one specific protocol for each method, and it is quite possible that protocol variations (e.g., different antibody for MeDIP-seq, different elution procedure for MethylCap-seq or different size selection for RRBS) would produce different results.
Our study also reinforces the importance of sequencing depth as a key parameter determining the power to detect differential methylation with any of the sequencing-based methods. To allow for a fair and practically relevant comparison, we sequenced ~30-40 million reads for each sample and method. However, it became evident that deeper sequencing would identify further DMRs, especially for MeDIP-seq and MethylCap-seq ( Supplementary Fig. 11 ). For disease-centered studies it is therefore necessary to make an informed decision about how to distribute the available resources between sequencing fewer samples more deeply and sequencing more samples less deeply. Such a decision can be guided by statistical power calculations when some prior knowledge exists about the characteristics of expected DMRs (e.g., magnitude of difference, location in CpG-rich versus CpG-poor genomic regions), or they can be dictated by practical considerations such as the number of available samples. In our experience and at current sequencing costs, a range of ~30-60 million reads per sample for MeDIP-seq and MethylCap-seq, and a range of ~10-20 million reads per sample for RRBS constitute a viable compromise between breadth and depth of sequencing. In contrast, whole-genome bisulfite sequencing 49 provides comprehensive genomic coverage at the cost of having to sequence over a billion reads per sample. On the other end of the spectrum, low sequencing depths are often sufficient to detect strong differences such as global loss of DNA methylation but do not provide reliable locus-specific information 50 .
Genome-wide studies tend to ignore repetitive regions due to technical difficulties, and the few studies that focused specifically on mapping DNA methylation in repetitive regions did so at relatively low coverage [51] [52] [53] . The current data set was well-suited to analyze DNA methylation in repetitive regions because the joint results obtained by three different experimental methods helped us to control for technical artifacts that can burden the analysis of repetitive DNA. We observed that repeat sequences are most highly methylated when they are CpG rich and highly prevalent in the human genome (Supplementary Data 2) . In contrast, the DNA methylation levels varied widely among repeat sequences that are either CpG poor or infrequent in the genome. These results lend support to the hypothesis that DNA methylation provides a mechanism for keeping active retrotransposons in check 54 . They also argue for a highly specific mechanism of repeat repression, which targets DNA methylation mostly to those repeat sequences that threaten genome integrity, whereas many 'benign' repeat sequences may remain unmethylated.
In summary, we benchmarked four methods for genome-scale DNA methylation mapping in terms of their accuracy and power to detect DNA methylation differences. These results will facilitate the selection of suitable methods for studying the role of DNA methylation in disease and development.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/.
Note: Supplementary information is available on the Nature Biotechnology website.
Instead, we used a statistical test to compare two samples directly with each other. For a given region with RRBS data, we count the number of methylated vs. unmethylated CpGs in both samples and perform Fisher's exact test to obtain a p-value that is indicative of the likelihood of the region being a DMR. Similarly, for MeDIP-seq and MethylCap-seq we count the numbers of reads that align inside the region for both samples and use Fisher's exact test to contrast these values with the total numbers of reads that align elsewhere in the genome. And for the Infinium assay we use a paired-samples t-test to compare the two samples' β-values of all Infinium probes inside the region. These tests are performed on a large number of genomic regions in parallel (e.g., on all CpG islands), and the p-values are corrected for multiple testing using the q-value method 62 . Genomic regions with a q-value of less than 0.1 are flagged as hypermethylated or hypomethylated (depending on the directionality of the difference), but only if the absolute DNA methylation difference exceeds 20 percentage points (for RRBS and Infinium) or if there is at least a twofold difference in the read number (for MeDIP-seq and MethylCap-seq). These thresholds were chosen by their practical utility in a number of comparisons between different cell types and have no further justification. We also mark genomic regions with insufficient sequencing coverage, but do not exclude them from DMR analysis. For MeDIP-seq and MethylCap-seq we require at least ten reads per 10 million total reads for the sample with higher read coverage, and for RRBS we require a minimum of five CpGs with at least five reads each in both samples.
This statistical approach to DMR identification requires us to define sets of genomic regions on which the analysis is being performed. We pursued a two-way strategy to maximize the chances of finding interesting DMRs. One the one hand, we focused specifically on CpG islands and gene promoters, which are prime candidates for epigenetic regulation. This approach provides increased statistical power for regions with well-known functional roles because the relatively low number of CpG islands and gene promoters reduces the burden of multiple-testing correction compared to the genomewide case. On the other hand, we used a 1-kilobase tiling of the genome to detect DMRs that are located outside of any candidate regions. And to cast an even wider net, we collected a comprehensive set of 13 types of genomic regions, which includes not only CpG islands and gene promoters, but also CpG island shores 31 , enhancers 63 , evolutionary conserved regions and other types of genomic regions. DMR data for all of these region sets were calculated using a set of Python and R scripts and are available online (http://meth-benchmark.computational-epigenetics.org/).
Experimental validation.
Based on the CpG islands that were detected as differentially methylated between the two ES cell lines ( Fig. 5) , we manually selected eight method-specific DMRs for experimental validation. To that end, those CpG islands that were identified as statistically significant DMRs by one method (but not by the other two methods) were visually inspected in the UCSC Genome Browser, and regions were selected for validation only if the data fully supported their classification as method-specific DMRs. In particular, regions were not selected if a second method already picked up a suggestive but insignificant trend in the same direction as the first method, or when the data of the first method already suggested that the DMR was a false-positive hit (e.g., because of contradictory trends in the vicinity of the DMR). Experimental validation was performed by clonal bisulfite sequencing following established protocols 64 . Primers were designed using MethPrimer 65 such that the amplicon overlapped with those CpGs that exhibited the highest levels of differential methylation according to our original data. To prepare for bisulfite sequencing, 1 μg of DNA was bisulfite-converted using the EpiTect kit (Qiagen); 50 ng of bisulfite-converted DNA was PCR-amplified (Supplementary Data 1 for primer sequences); and purified amplicons were cloned using the TOPO TA cloning kit (Invitrogen). For each region an average of 11 clones were randomly chosen for sequencing. All sequencing data were processed using the BiQ Analyzer software 66 , and the results are summarized in Supplementary Data 1.
Analysis of repetitive DNA. Repeat sequences were obtained from database version 14.07 of RepBase Update 39 , which is publicly available online (http://www.girinst.org/server/RepBase/index.php). From a total of 11,670 prototypic repeat sequences we selected those 1,267 that were annotated either to human or to its ancestors in the taxonomic tree, and we combined these prototypic repeat sequences into a pseudo-genome file. Maq with default parameters was used to align MeDIP-seq, MethylCap-seq, RRBS, ChIP-seq (H3K4me3) and whole-cell extract (WCE) sequencing reads against this pseudo-genome 59 . For RRBS, both the reads and the reference genome were bisulfite-converted in silico before the alignment. The epigenetic status of each prototypic repeat sequence was quantified as follows: (i) For MeDIP-seq, MethylCap-seq and ChIP-seq we calculated the odds ratios relative to the WCE data. (ii) For RRBS we computed the number of methylated CpGs, total number of CpG measurements and percentage of DNA methylation based on the comparison of the aligned reads with the prototypic repeat sequence.
We discarded rare repeats with WCE coverage below 100 aligned reads or RRBS coverage below 25 CpG measurements, resulting in 553 prototypic repeat sequences that were used for further analysis. Among these were 97 LINE class sequences (92 of them from the L1 family), 51 SINEs (48 of them from the Alu family), 6 SVAs, 62 DNA repeats, 15 satellite repeats, 315 LTRs, 1 low-complexity repeat and 6 RNA repeats (Supplementary Data 2) . To quantify differential methylation between a pair of MeDIP-seq and MethylCap-seq samples, we calculated the pairwise odds ratio of the read coverage for each prototypic repeat sequence. The absolute DNA methylation difference was used in the case of RRBS (Supplementary Data 3) . The significance of the difference was assessed using Fisher's exact test in the same way as for the nonrepetitive genome (described above).
